UK markets closed

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.5300-0.1000 (-2.16%)
At close: 04:00PM EDT
4.5101 -0.02 (-0.44%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.6300
Open4.6200
Bid4.4900 x 200
Ask4.5600 x 200
Day's range4.4900 - 4.7350
52-week range3.1700 - 5.7500
Volume2,277,526
Avg. volume3,190,577
Market cap1.255B
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.08
  • GlobeNewswire

    MannKind Announces CFO Transition

    Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through December 31, 2024Christopher Prentiss appointed Chief Financial Officer, effective April 22, 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lu

  • Insider Monkey

    Jim Cramer Says You Should Avoid These 11 Stocks

    In this article, we will take a detailed look at Jim Cramer Says You Should Avoid These 11 Stocks. For a quick overview of such stocks, read our article Jim Cramer Says You Should Avoid These 5 Stocks. Jim Cramer in his latest program took a jab at the Department of Justice and Washington authorities in general, calling regulators […]

  • GlobeNewswire

    INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

    Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumpsSubjects utilizing inhaled insulin experienced a 22% decrease in mean glucose excursions in the first two hours compared to the standard of care17-week primary endpoint results will be presented during a 90-minute symposium at the American Diabetes Association’s Scientific Sessions in June DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 11, 202